TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Novartis has hit the primary endpoint in what it says is the largest randomized, controlled study to date to treat secondary progressive multiple sclerosis…

Investors have plowed another $130 million into a Series B to back the startup that’s led by Genentech vets, which brings its total raised to almost $350…

In our EuroBiotech roundup this week, Clal benefits from Pfizer-Medivation deal, Hansa posts Phase II data, NeuroVive jettisons COO and more.

In this week's EuroBiotech Report, FDA knocks Sanofi, Zealand off track, Gilead, Galapagos start Phase III program, Promethera plans IPO and more.